Studies in transgenic spinocerebellar ataxia type 3 mice have demonstrated that IGF-1 therapy is less effective than GH treatment [62], likely reflecting distinct regulatory mechanisms by which GH and IGF-1 confer neuroprotection. This evidence concerns the gene IGF1 and cerebellar ataxia.